Phase 2 Data On Provectus's PV-10 For Metastatic Melanoma To Be Presented At Two Upcoming Conferences

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences. On June 21, 2011, Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA and Principal Investigator for our Phase 2 trial site at St. Luke's, will deliver an oral presentation at the 7th EADO (European Association of Dermato-Oncology) Conference in Nantes, France...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/Zzvfke7gNYc/228741.php

fat loss longevity